David Tapolczay - Conduit Pharmaceuticals CEO Director
| CDTTW Stock | 0.01 0.0002 1.83% |
CEO
David Tapolczay is CEO Director of Conduit Pharmaceuticals
| Age | 65 |
| Address | 4995 Murphy Canyon Road, San Diego, CA, United States, 92123 |
| Phone | 760 471 8536 |
| Web | https://www.conduitpharma.com |
David Tapolczay Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Tapolczay against Conduit Pharmaceuticals stock is an integral part of due diligence when investing in Conduit Pharmaceuticals. David Tapolczay insider activity provides valuable insight into whether Conduit Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Conduit Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Conduit Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Tapolczay over three months ago Disposition of tradable shares by David Tapolczay of Conduit Pharmaceuticals subject to Rule 16b-3 |
Conduit Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (3.2202) % which means that it has lost $3.2202 on every $100 spent on assets. This is way below average. Conduit Pharmaceuticals' management efficiency ratios could be used to measure how well Conduit Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to climb to -0.97 in 2024. At this time, Conduit Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 1.6 M in 2024, whereas Intangible Assets are likely to drop 4,000 in 2024.Similar Executives
| Found 6 records | CEO Age | ||
| Ryan Watts | Denali Therapeutics | 48 | |
| Dietrich MBA | DiaMedica Therapeutics | 53 | |
| Marino MBA | Dianthus Therapeutics | 58 | |
| Thomas Lingelbach | Valneva SE ADR | 61 | |
| Bonnie Anderson | Veracyte | 66 | |
| Dominick Esq | Vericel Corp Ord | 60 | |
Management Performance
| Return On Asset | -3.22 |
Conduit Pharmaceuticals Leadership Team
Elected by the shareholders, the Conduit Pharmaceuticals' board of directors comprises two types of representatives: Conduit Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Conduit. The board's role is to monitor Conduit Pharmaceuticals' management team and ensure that shareholders' interests are well served. Conduit Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Conduit Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Tapolczay, CEO Director | ||
| James Bligh, Interim Director | ||
| Adam Sragovicz, Chief Officer | ||
| Joanne Holland, Chief Officer | ||
| Bill Begien, Senior Relations |
Conduit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Conduit Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -3.22 | ||||
| Number Of Shares Shorted | 36.58 K | ||||
| EBITDA | (324 K) | ||||
| Net Income | (535 K) | ||||
| Total Debt | 985 K | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (7.72 M) | ||||
| Beta | 2.12 | ||||
| Total Asset | 7.22 M | ||||
| Retained Earnings | (11.3 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.